Moderna Stock Target Price and Analyst Consensus

MRNA
 Stock
  

USD 149.95  7.10  4.97%   

The current analyst and expert consensus on Moderna is Hold with 5 hold recommendations. The current projected Moderna target price consensus is 257.23 with 13 analyst opinions. One of the most common ways Moderna analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Moderna vendors, executives, and/or customers. Moderna recommendation module provides expert sentiment on the projected Moderna target price to derive its highest and lowest estimates based on target price standard deviation of 119.817. Additionally, see Macroaxis Advice on Moderna to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
Refresh
The current year Gross Profit is expected to grow to about 17.1 B. The current year Profit Margin is expected to grow to 0.71. Moderna Receivables is projected to increase significantly based on the last few years of reporting. The past year's Receivables was at 3.23 Billion. The current year Accounts Payable is expected to grow to about 325.8 M, whereas Accumulated Other Comprehensive Income is forecasted to decline to (24.6 M).

Moderna Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moderna target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moderna target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions13
Lowered Outlook0
Raized Outlook0
Hold
Most Moderna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Moderna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Moderna, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Moderna Target Price Projection

Moderna's current and average target prices are 149.95 and 257.23, respectively. The current price of Moderna is the price at which Moderna is currently trading. On the other hand, Moderna's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Moderna Market Quote on 2nd of July 2022

Low Price139.54Odds
High Price151.1Odds

149.95

Target Price

Analyst Consensus On Moderna Target Price

Low Estimate86.0Odds
High Estimate506.0Odds
Number of Analysts13
Standard Deviation119.817

257.23

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Moderna and the information provided on this page.

Moderna Analyst Ratings

Moderna's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Moderna stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Moderna's financials, market performance, and future outlook by experienced professionals. Moderna's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Moderna Target Price Projections

Moderna's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Moderna and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Moderna depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Moderna including analysis of its current option contracts.
Moderna's latest option contracts expiring on 2022-07-08 are carrying combined implied volatility of 70.11 with a put-to-call open interest ratio of 1.59 over 172 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on 2022-07-08. The current put volume is at 6473, with calls trading at the volume of 9263. This yields a 0.7 put-to-call volume ratio. The Moderna option chain provides detailed quote and price information for the current Moderna option contracts. It shows all of Moderna's listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2022-07-08 Option Contracts

Moderna option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Moderna's lending market. For example, when Moderna's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Moderna, he or she must hedge the risk by shorting Moderna stock over its option's life.
The chart above shows Moderna's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Moderna's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Moderna's option, there is no secondary market available for investors to trade.

Moderna Maximum Pain Price across 2022-07-08 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Moderna close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Moderna's stock options are financial instruments that give investors the right to buy or sell shares of Moderna common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Moderna stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Moderna's stock price goes up or down, the stock options follow.
Additionally, see Macroaxis Advice on Moderna to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Moderna In The Money Call Balance

When Moderna's strike price is surpassing the current stock price, the option contract against Moderna stock is said to be in the money. When it comes to buying Moderna's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' options written on Moderna are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Moderna Current Options Market Mood

Moderna's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Moderna Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Moderna's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Moderna's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Moderna's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional Moderna Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Moderna is a key component of Moderna valuation and have some predictive power on the future returns of a Moderna.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Moderna's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Moderna in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
145.58149.93154.28
Details
Intrinsic
Valuation
LowReal ValueHigh
134.95175.95180.30
Details
Naive
Forecast
LowNext ValueHigh
160.16164.51168.86
Details
Earnings
Estimates (10)
LowProjected EPSHigh
22.2526.3228.11
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moderna. Your research has to be compared to or analyzed against Moderna's peers to derive any actionable benefits. When done correctly, Moderna's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Moderna.

Additional Moderna Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Moderna is a key component of Moderna valuation and have some predictive power on the future returns of a Moderna.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Moderna's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Moderna in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
145.58149.93154.28
Details
Intrinsic
Valuation
LowReal ValueHigh
134.95175.95180.30
Details
Naive
Forecast
LowNext ValueHigh
160.16164.51168.86
Details
Earnings
Estimates (10)
LowProjected EPSHigh
22.2526.3228.11
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moderna. Your research has to be compared to or analyzed against Moderna's peers to derive any actionable benefits. When done correctly, Moderna's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Moderna.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Investor Favorites
Invested less than 1 share
Macroaxis Index
Invested few shares
Giant Impact
Invested few shares
Additionally, see Macroaxis Advice on Moderna to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
The data published in Moderna's official financial statements usually reflect Moderna's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moderna. For example, before you start analyzing numbers published by Moderna accountants, it's critical to develop an understanding of what Moderna's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moderna's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moderna. Please utilize our Beneish M Score to check the likelihood of Moderna's management to manipulate its earnings.